New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Subscribe To Our Newsletter & Stay Updated
